Abstract 3769
Background
Lymphocytes are an important portion of the cell-mediated immune system, and play a significant role in immune responses to cancer. We investigated whether peripheral lymphocyte are associated with disease-free survival, gastric cancer-specific survival, and overall survival in surgically resected gastric cancer.
Methods
We retrospectively evaluated stage II-III gastric cancer patients who underwent curative surgical resection to analyze correlations among absolute lymphocyte counts and prognosis. Multivariable regression models adjusted for age, performance status, cancer stage, neoadjuvant/adjuvant chemotherapy use, HER2 expression were used to evaluate associations between absolute lymphocyte count, disease-free survival, gastric cancer-specific overall survival, and overall survival.
Results
A total of 338 stage II-III gastric cancer patients were diagnosed from January 2011 to December 2015. At the time of diagnosis, lymphopenic were 31 (9.1%) and no patients were neutropenic. Nearly one quarter (25.1%) were ever neutropenic (ANC <1.0 K/μL) and nearly half (52.6%) were lymphopenic (ALC <1.0 K/μL) with a mean minimum ALC value of 1.00 K/μL. On multivariable analysis, ever lymphopenia predicted higher recurrence rate [HR = 12.4; 95% CI 4.9-31.3], higher gastric cancer-specific mortality [HR = 22.7; 95% CI 6.5-79.1], and higher overall mortality [HR = 36.6; 95% CI 10.3-130.0]. Five year disease-free survival was 57% for patients who were ever lymphopenic versus 96% for those who were not. Fiver year gastric cancer specific overall survival was 65% versus 98% for ever lymphopenic and never lymphopenic patients, respectively.
Conclusions
Higher peripheral lymphocyte counts predicted lower recurrence rate and better overall survival from potentially curable gastric cancer, suggesting that immune function may enhance the effectiveness of non-advanced gastric cancer treatment.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3773 - Impact of centralisation of national cancer services on patient outcomes for hepatobiliary cancers in Ireland 2000 – 2016
Presenter: David O Reilly
Session: Poster Display session 2
Resources:
Abstract
3180 - Genomic analysis of hepatobiliary lithiasis associated cholangiocarcinoma revealed a distinct subtype feature.
Presenter: Lunda Gu
Session: Poster Display session 2
Resources:
Abstract
4891 - Comparison of the impact of stereotactic body radiation therapy vs. radiofrequency ablation on liver function in patients with single hepatocellular carcinoma: A propensity score matching analysis
Presenter: Masayuki Ueno
Session: Poster Display session 2
Resources:
Abstract
3203 - Exploratory analysis based on tumor location and early metabolic tumor response of REACHIN, a randomized double-blinded placebo-controlled phase II trial of regorafenib after failure of gemcitabine/platinum-based chemotherapy for advanced and metastatic biliary tract tumors.
Presenter: Anne Demols
Session: Poster Display session 2
Resources:
Abstract
1602 - Predictive Value of Neutrophil-Lymphocyte Ratio (NLR) And Platelet-Lymphocyte Ratio (PLR) In Hepatocellular Carcinoma (HCC) Patients Treated with Nivolumab (N)
Presenter: Sirish Dharmapuri
Session: Poster Display session 2
Resources:
Abstract
2848 - Preliminary Safety and Pharmacokinetics of a New Lysosomotropic Oral Agent, GNS561, in a First-in-Human Study in Advanced Primary Liver Cancer Patients
Presenter: Ahmad Awada
Session: Poster Display session 2
Resources:
Abstract
1396 - A phase 1b trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC): updated results
Presenter: Josep Llovet
Session: Poster Display session 2
Resources:
Abstract
1139 - Multicentric prospective study of validation of angiogenesis-related gene polymorphisms in HCC patients treated with sorafenib: Final results of INNOVATE study
Presenter: Andrea Casadei-gardini
Session: Poster Display session 2
Resources:
Abstract
4688 - Prognostic and predictive factors from the phase 3 CELESTIAL trial of cabozantinib (C) versus placebo (P) in previously treated advanced hepatocellular carcinoma (aHCC)
Presenter: Tim Meyer
Session: Poster Display session 2
Resources:
Abstract
1492 - A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.
Presenter: David Pinato
Session: Poster Display session 2
Resources:
Abstract